

08. Maternal and infant TB: advancing our understanding of pathogenesis, treatment and prevention

**THE 46TH UNION
WORLD CONFERENCE
ON LUNG HEALTH**

CAPE TOWN, SOUTH AFRICA
2-6 DECEMBER 2015

Friday, 04 December 2015, 13:30 - 15:00

Room Roof Terrace

| | |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Type of session | Symposium |
| Track | TB in vulnerable and special populations |
| Track2 (optional) | TB other |
| Description | Increased recognition of women's health issues and innovative approaches to research have breathed new life into maternal-infant TB research. TB is a leading cause of maternal and infant mortality, yet many TB providers and researchers are unfamiliar with the pathogenesis, treatment and prevention of TB in these populations. Pharmacokinetic/pharmacodynamic (PK/PD) differences in pregnant women and infants with TB will be highlighted. This symposium will feature emerging research and novel approaches—in both basic science and clinical trials—that are moving the maternal-infant TB agenda forward |
| Target audience | <ol style="list-style-type: none"> 1. TB policymakers and program implementers 2. Healthcare providers and advocates 3. TB researchers and educators |
| Objectives | <ol style="list-style-type: none"> 1. To review current research in the pathogenesis, prevention and treatment of maternal-infant TB 2. To discuss PK/PD principles pertaining to TB drugs in pregnancy and young children 3. To present innovative research approaches used to extend benefits of TB research to pregnant women and infants |
| Keywords | Maternal TB; infant TB; pharmacokinetics |
| Coordinator(s) | Jyoti Mathad (USA), Adrie Bekker (South Africa) |
| Chair(s) | Anneke Hesseling (South Africa), Grace John-Stewart (USA) |
| Presentations | <p>13:30 - 13:40 Challenges in the management of maternal and perinatal TB: cases from the field Shilpa Naik (India)</p> <p>13:45 - 13:55 Current research on the pathophysiology, immunology, prevention and treatment of TB in pregnant women Jyoti Mathad (USA), Amita Gupta (USA)</p> <p>14:00 - 14:10 TB-HIV treatment during pregnancy: does drug metabolism change? Rose Kosgei (Kenya)</p> <p>14:15 - 14:25 Using a population modeling approach to assess the pharmacology of TB drugs in pregnant women Kelly Dooley (USA), Rada Savic (USA)</p> <p>14:30 - 14:40 The pharmacokinetics and treatment of first line TB drugs for infants Adrie Bekker (South Africa)</p> <p>14:45 - 15:00 Discussion</p> |